Unknown

Dataset Information

0

Real-World Outcomes and Factors Associated With the Second-Line Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma.


ABSTRACT: This retrospective observational study was designed to evaluate overall survival in a real-world patient population and to identify predictive factors associated with receipt of second-line therapy. A retrospective analysis of electronic medical records (Flatiron Health, New York) was conducted among patients initiating first-line therapy from January 1, 2013, through April 30, 2018. Eligible patients were diagnosed with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma and ≥18 years of age at the time of treatment initiation. Patients alive 45 days after discontinuation of first-line therapy were considered potentially eligible for continued therapy and were categorized into those who received and those who did not receive second-line therapy. Survival analyses were conducted using Kaplan-Meier method and log-rank test without adjusting for any baseline covariates. Factors associated with further treatment were evaluated using logistic regression. A total of 3850 patients met eligibility criteria. Among the 2516 patients available to receive second-line therapy, 1515 (60.2%) received second-line therapy and 1001 (39.8%) did not receive further therapy. Among those potentially eligible to receive second-line therapy, median survival was 15.4 months (95% confidence interval [CI]: 14.6-16.0) from initiation of first-line therapy for those who received second-line therapy and 10.0 months (95% CI: 9.3-10.7) for those who did not. Longer duration of first-line therapy (≥169 vs ≤84 days), HER2-positive tumors, initially diagnosed with stage IV disease, less weight loss during first-line therapy, and younger age were associated with receipt of second-line therapy (all P < .001). Longer survival was associated with multiple lines of therapy; however, these results should be interpreted with caution, and no causal relationship can be inferred.

SUBMITTER: Barzi A 

PROVIDER: S-EPMC6503607 | biostudies-literature | 2019 Jan-Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Real-World Outcomes and Factors Associated With the Second-Line Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma.

Barzi Afsaneh A   Hess Lisa M LM   Zhu Yajun E YE   Liepa Astra M AM   Sugihara Tomoko T   Beyrer Julie J   Chao Joseph J  

Cancer control : journal of the Moffitt Cancer Center 20190101 1


This retrospective observational study was designed to evaluate overall survival in a real-world patient population and to identify predictive factors associated with receipt of second-line therapy. A retrospective analysis of electronic medical records (Flatiron Health, New York) was conducted among patients initiating first-line therapy from January 1, 2013, through April 30, 2018. Eligible patients were diagnosed with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma a  ...[more]

Similar Datasets

| S-EPMC5224844 | biostudies-literature
| S-EPMC8450614 | biostudies-literature
| S-EPMC10092493 | biostudies-literature
2022-02-06 | GSE126304 | GEO
| S-EPMC9632317 | biostudies-literature
| S-EPMC6527138 | biostudies-literature
| S-EPMC6384095 | biostudies-literature
| S-EPMC10201153 | biostudies-literature
| S-EPMC7360144 | biostudies-literature
| S-EPMC9985926 | biostudies-literature